{"organizations": [], "uuid": "88d21462a13cd3edcc06b05a96acdea25d864b42", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180123.html", "section_title": "Archive News &amp; Video for Tuesday, 23 Jan 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-bone-therapeutics-cash-and-cash-eq/brief-bone-therapeutics-cash-and-cash-equivalents-of-eur-8-4-mln-at-end-of-2017-idUSFWN1PH182", "country": "US", "domain_rank": 408, "title": "BRIEF-Bone Therapeutics Cash And Cash Equivalents Of EUR 8.4 Mln At End Of 2017", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.903, "site_type": "news", "published": "2018-01-23T14:11:00.000+02:00", "replies_count": 0, "uuid": "88d21462a13cd3edcc06b05a96acdea25d864b42"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-bone-therapeutics-cash-and-cash-eq/brief-bone-therapeutics-cash-and-cash-equivalents-of-eur-8-4-mln-at-end-of-2017-idUSFWN1PH182", "ord_in_thread": 0, "title": "BRIEF-Bone Therapeutics Cash And Cash Equivalents Of EUR 8.4 Mln At End Of 2017", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}, {"name": "gdynia newsroom", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Jan 23 (Reuters) - BONE THERAPEUTICS:\n* REG-BONE THERAPEUTICS SA : PROVIDES BUSINESS OUTLOOK AND ANNOUNCES ITS FINANCIAL CALENDAR FOR 2018\n* COMPLETION OF RECRUITMENT IN ITS PHASE IIA SPINAL FUSION TRIAL WITH ALLOB(®), FOLLOWING POSITIVE INTERIM DATA, EXPECTED IN Q1\n* FINAL RESULTS EXPECTED IN PHASE I/IIA TRIAL OF ALLOB(®) IN DELAYED UNION FRACTURES IN H1\n* CASH UTILIZATION FOR FULL YEAR 2017 BELOW GUIDANCE * CASH AND CASH EQUIVALENTS OF EUR 8.4 MILLION END OF 2017 * ‍INTERIM RESULTS FOR FIRST 44 PATIENTS IN PHASE III STUDY OF PREOB(®) IN OSTEONECROSIS AFTER ONE-YEAR FOLLOW-UP, WITH POTENTIAL FOR EARLY TRIAL STOP, IN H2​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-01-23T14:11:00.000+02:00", "crawled": "2018-01-24T15:52:06.000+02:00", "highlightTitle": ""}